




RealRate

# PHARMACEUTICAL 2020

Statera Biopharma Inc.  
Rank 313 of 358





RealRate

# PHARMACEUTICAL 2020

## Statera Biopharma Inc. Rank 313 of 358



The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Statera Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is -125%, being 162% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	2,003
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,521
Liabilities, Non-Current	0
Other Assets	19
Other Compr. Net Income	91
Other Expenses	0
Other Liabilities	0
Other Net Income	-611
Other Revenues	922
Property and Equipment	16
Research and Development	1,656
Selling, General and Administrative Expense	1,818

Output Variable	Value in 1000 USD
Assets	2,037
Liabilities	1,521
Expenses	3,474
Revenues	922
Stockholders Equity	516
Net Income	-3,163
Comprehensive Net Income	-3,117
Economic Capital Ratio	-125%